---

Treatment Plan for Myelodysplastic Syndromes (MDS)

Overview

Only allogeneic hematopoietic cell transplantation (allo-HCT) offers the possibility of cure.

---

Step 1: Risk Stratification (IPSS-R)

---

Step 2: Treatment by Risk Group

🔵 Lower-Risk MDS (IPSS-R Very Low, Low, Intermediate-1)

A. Observation (Watchful Waiting)

• Appropriate for asymptomatic patients with mild cytopenias and no significant symptoms.

B. Anemia Management

C. Transfusion Support

• Red blood cell (RBC) transfusions for symptomatic anemia.
• Platelet transfusions for hemorrhage or severe thrombocytopenia.
• Iron chelation (deferasirox or deferoxamine) for patients with transfusion-related iron overload (serum ferritin >1,000–2,500 ng/mL, prolonged RBC transfusion dependence).

---

🔴 Higher-Risk MDS (IPSS-R High, Very High; also Intermediate-2)

A. Hypomethylating Agents (HMAs) — Standard of Care

• Azacitidine showed overall survival benefit vs. conventional care (AZA-001 trial).
• At least 4–6 cycles should be given before declaring failure.
• ± Venetoclax (BCL-2 inhibitor): Added based on patient status and tolerance; improves response rates in combination with HMAs.

B. Targeted Agents (Mutation-Specific)

C. Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

• Recommended for all eligible patients with higher-risk MDS.
• Eligibility: Generally age <70–75, good performance status (ECOG 0–1), no major organ dysfunction.
• Pre-transplant cytoreduction options:
  • HMA ± venetoclax
  • HMA + ivosidenib/olutasidenib (if mIDH1)
  • High-intensity chemotherapy (induction similar to AML regimens)
  • CPX-351 (for aggressive disease burden reduction)
• Reduced-intensity conditioning (RIC) used for older/less fit patients.

D. Intensive Chemotherapy

• AML-type induction (e.g., 7+3 regimen) for select fit patients as bridge to transplant.

---

🟡 Post-HMA Failure / Relapsed-Refractory MDS

• Clinical trial enrollment is essential (most important recommendation).
• Single-agent ivosidenib or olutasidenib (if mIDH1).
• Re-evaluation with bone marrow biopsy + molecular testing to guide therapy.
• Consider allo-HCT if not previously performed.

---

Step 3: Special Scenarios

---

Step 4: Supportive Care (All Risk Groups)

---

FDA-Approved Agents for MDS (2025)

---

Key Principles

1. Risk stratify first using IPSS-R (or IPSS-M if molecular data available).
2. Lower-risk → symptom/cytopenia management; higher-risk → modify disease course.
3. Allo-HCT is the only cure — always assess eligibility.
4. Clinical trial enrollment is strongly encouraged, especially post-HMA failure.
5. Reassess after 4–6 HMA cycles; consider bone marrow biopsy + molecular testing at progression.

---

---

Allo-HCT in Elderly Patients with MDS

Short Answer: Yes — but with careful patient selection

---

What the Evidence Says

Upper Age Limit

"In the modern era of HCT, age may, in fact, just be a number." — Hadjis & McCurdy, 2025 (PMID: 40488822)

---

Conditioning Regimens by Age / Fitness

---

How to Determine Eligibility — Not Age, But Fitness

A fit 72-year-old with no comorbidities is a better candidate than a frail 60-year-old with heart failure.

---

Outcomes in Elderly Patients

• 5-year OS: 49.3% in ≥65 yr vs. 56.7% in <65 yr → no significant difference
• 5-year PFS: 48.4% vs. 56.2% → no significant difference
• NRM was ~33.8% in elderly — comparable to younger group
• Relapse risk was higher in ≥65 yr (HR 2.77, p=0.035), especially in very high-risk IPSS-R

• RIC regimens
• Post-transplant cyclophosphamide (PTCy) for GVHD prevention
• Abatacept as GVHD prophylaxis
• HLA-haploidentical donors (expanding donor pool)
• Matched unrelated donors now equal to sibling donors
• Azacitidine/venetoclax pre-transplant bridge (better remission induction in older patients)

---

Risks Specific to Elderly Transplant Recipients

---

Practical Decision Framework

Higher-risk MDS (IPSS-R High/Very High) + Age ≤75
        ↓
Comprehensive geriatric assessment
        ↓
Fit (HCT-CI ≤2, ECOG 0–1, good organ function)?
   YES → RIC allo-HCT (preferred)
         Bridge with HMA ± venetoclax while awaiting donor
   NO  → HMA-based therapy (azacitidine ± venetoclax)
         Clinical trial
         Palliative/supportive care

---

Key Takeaways

1. Age ≤75 is the general guideline cutoff, but select centers transplant up to age 80 with appropriate patient selection.
2. RIC is the standard for elderly MDS patients — myeloablative conditioning is reserved for <55 years.
3. Frailty and comorbidity, not age, are the primary barriers — use HCT-CI + geriatric assessment.
4. Outcomes in well-selected elderly patients (≥65) are not significantly inferior to younger patients in modern series.
5. Pre-transplant bridge therapy (azacitidine ± venetoclax) improves remission depth and is often used while awaiting donor matching.
6. If transplant is not feasible → HMA therapy remains standard; clinical trial enrollment is strongly encouraged.

---